New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:24 EDTGSKGlaxoSmithKline upgraded to Buy from Hold at Argus
Argus upgraded GlaxoSmithKline to Buy from Hold following the announcement it will sell its oncology business to Novartis, purchase the Novartis Vaccine business and combine their Consumer Healthcare businesses into a joint venture. The firm said the swaps allow GlaxoSmithKline monetize its struggling oncology business and build on its strength. Price target is $65.
News For GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:20 EDTGSKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:01 EDTGSKPernix Therapeutics obtains six months U.S. pediatric exclusivity for Treximet
Subscribe for More Information
April 16, 2015
09:14 EDTGSKAdamis says albuterol HFA product study met clinical FEV1 primary endpoint
Subscribe for More Information
08:15 EDTGSKGlaxoSmithKline and Theravance announce launch of Anoro in Spain
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Anoro in Spain following the approval in Europe in May 2014. Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro Ellipta is a combination of two bronchodilators, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, in a single dry powder inhaler, the Ellipta. The approved dose of UMEC/VI is 55/22mcg. UMEC/VI has been developed under the 2002 LABA collaboration agreement between Glaxo Group Limited and Theravance.
April 15, 2015
11:53 EDTGSKGlaxoSmithKline initiated with a Sell at Societe Generale
April 7, 2015
07:14 EDTGSKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use